PB 122 of 2026

National Health (Price and Special Patient Contribution) Amendment Determination (No. 9) 2026

I, Mike Pope, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following Determination:

Dated 28 September 2026

MIKE POPE
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1 Name 1
2 Commencement 1
3 Authority 1
4 Schedules 1

Schedule 1—Amendments **2**

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022) *2*

Authorised Version F2026L01321 registered 29/09/2026

1 Name

This instrument is the *National Health (Price and Special Patient Contribution) Amendment Determination (No. 9) 2026*.

This instrument may also be cited as PB 122 of 2026.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	**Column 2**	**Column 3**
Provisions	**Commencement**	**Date/Details**
1. The whole of this instrument	1 October 2026	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under section 85B of the *National Health Act 1953.*

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Authorised Version F2026L01321 registered 29/09/2026

Schedule 1 – Amendments

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022)

1. Schedule 1 – omit entry for Amlodipine with atorvastatin

2. Schedule 1 – entry for Carbamazepine

Omit

Carbamazepine	Tablet 100 mg	Oral	Tegretol 100	100	4.85	6.98
	Tablet 200 mg	Oral	Tegretol 200	100	8.10	10.24

Insert

Carbamazepine	Tablet 100 mg	Oral	Tegretol 100	100	6.21	6.98

3. Schedule 1 – entry for Cefuroxime

Omit

Cefuroxime	Tablet 250 mg (as axetil)	Oral	Zinnat	20	5.27	11.16

Insert

Cefuroxime	Tablet 250 mg (as axetil)	Oral	Zinnat	20	4.31	9.13

4. Schedule 1 – entry for Desvenlafaxine

Omit

Desvenlafaxine	Tablet (extended release) 50 mg (as succinate)	Oral	Pristiq	28	6.45	10.64
	Tablet (extended release) 100 mg (as succinate)	Oral	Pristiq	28	7.92	12.11

Authorised Version F2026L01321 registered 29/09/2026

Insert

Desvenlafaxine	Tablet (extended release) 50 mg (as succinate)	Oral	Pristiq	28	6.45	10.64
	Tablet (extended release) 100 mg (as succinate)	Oral	Pristiq	28	7.02	10.73

5. Schedule 1 – entry for Dorzolamide with timolol

Omit

Dorzolamide with timolol	Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL	Application to the eye	Cosopt	1	7.93	8.68

Insert

Dorzolamide with timolol	Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL	Application to the eye	Cosopt	1	8.23	8.68

6. Schedule 1 – entry for Felodipine

Omit

Felodipine	Tablet 5 mg (extended release)	Oral	Plendil ER	30	3.75	7.36
	Tablet 10 mg (extended release)	Oral	Plendil ER	30	6.79	10.28

Insert

Felodipine	Tablet 2.5 mg (extended release)	Oral	Plendil ER	30	3.11	6.80

	Tablet 5 mg (extended release)	Oral	Plendil ER	30	3.75	7.36
	Tablet 10 mg (extended release)	Oral	Plendil ER	30	6.79	10.28

7. Schedule 1 – entry for Indometacin

Omit

Indometacin	Capsule 25 mg	Oral	Indocid	50	3.10	5.44

Insert

Indometacin	Capsule 25 mg	Oral	Indocid	50	4.53	5.44

8. Schedule 1 – entry for Levothyroxine

Omit

Levothyroxine	Tablet containing 50 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	8.03	9.07
	Tablet containing 75 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	8.17	9.22
	Tablet containing 100 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	8.32	9.36
	Tablet containing 200 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	9.76	10.80

Authorised Version F2026L01321 registered 29/09/2026

Insert

Levothyroxine	Tablet containing 50 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	7.12	8.04
	Tablet containing 75 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	7.24	8.17
	Tablet containing 100 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	7.38	8.30
	Tablet containing 200 micrograms anhydrous levothyroxine sodium	Oral	Oroxine	200	8.65	9.57

9. Schedule 1 – entry for Olanzapine

Omit

Olanzapine	Tablet 2.5 mg	Oral	Zyprexa	28	3.08	10.53
	Tablet 5 mg	Oral	Zyprexa	28	4.00	13.56
	Tablet 7.5 mg	Oral	Zyprexa	28	4.76	9.34
	Tablet 10 mg	Oral	Zyprexa	28	6.34	10.92
	Wafer 5 mg	Oral	Zyprexa Zydis	28	4.00	13.56
	Wafer 10 mg	Oral	Zyprexa Zydis	28	6.34	15.60
	Wafer 15 mg	Oral	Zyprexa Zydis	28	9.52	20.36
	Wafer 20 mg	Oral	Zyprexa Zydis	28	12.69	23.52

Insert

Olanzapine	Tablet 2.5 mg	Oral	Zyprexa	28	3.08	10.53
	Tablet 5 mg	Oral	Zyprexa	28	4.00	13.56
	Tablet 7.5 mg	Oral	Zyprexa	28	4.21	8.26
	Tablet 10 mg	Oral	Zyprexa	28	5.61	9.66

	Wafer 5 mg	Oral	Zyprexa Zydis	28	4.00	13.56
	Wafer 10 mg	Oral	Zyprexa Zydis	28	6.34	15.60
	Wafer 15 mg	Oral	Zyprexa Zydis	28	9.52	20.36
	Wafer 20 mg	Oral	Zyprexa Zydis	28	12.69	23.52

10. Schedule 1 – entry for Olmesartan with amlodipine

Omit

Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	Oral	Sevikar 20/5	30	3.62	7.34
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	Oral	Sevikar 40/5	30	5.18	8.90
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	Oral	Sevikar 40/10	30	5.56	9.28

Insert

Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	Oral	Sevikar 20/5	30	3.62	7.34
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	Oral	Sevikar 40/5	30	4.50	7.73
	Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate)	Oral	Sevikar 40/10	30	4.82	8.04

11. Schedule 1 – entry for Salbutamol

Omit

Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20	Inhalation	Ventolin Nebules	1	2.98	4.54
	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20	Inhalation	Ventolin Nebules	1	3.11	4.66
	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by mouth	Asmol CFC-Free with dose counter	1	5.42	5.85
	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by mouth	Ventolin CFC-Free with dose counter	1	5.42	8.21

Insert

Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by mouth	Asmol CFC-Free with dose counter	1	5.42	5.85
	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by mouth	Ventolin CFC-Free with dose counter	1	5.42	8.21

12. Schedule 1 – entry after for Sumatriptan

Insert

Tamoxifen	Tablet 20 mg (as citrate)	Oral	Nolvadex-D	30	4.40	8.19

Authorised Version F2026L01321 registered 29/09/2026